New imaging tracer could reveal how chemotherapy affects lymphoma blood vessels

NCT ID NCT02490891

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a special PET scan tracer called 18F-RGD-K5 in 21 people with lymphoma. The tracer highlights blood vessel growth (angiogenesis) in tumors. Scans were done before and after two rounds of chemotherapy to see how the tumors changed. The goal was to learn whether this imaging method can measure treatment response, not to treat the disease directly.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
18F-RGD-K5 tracer
What this could lead to
If successful, this imaging method could help doctors see how well chemotherapy is working by tracking tumor blood vessel changes.
What could go wrong
This is a small, early-phase study with only 21 participants, so results may not apply to all lymphoma patients. The tracer is experimental and not yet proven to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Centre Henri Becquerel

    Rouen, 76038, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.